



TITLE:

Staging Cardiac Damage in Patients With Hypertension

AUTHOR(S):

Seko, Yuta; Kato, Takao; Shiba, Masayuki; Morita, Yusuke; Yamaji, Yuhei; Haruna, Yoshizumi; Nakane, Eisaku; Haruna, Tetsuya; Inoko, Moriaki

CITATION:

Seko, Yuta ...[et al]. Staging Cardiac Damage in Patients With Hypertension. Hypertension 2019, 74(6): 1357-1365

ISSUE DATE:

2019-12

URL:

<http://hdl.handle.net/2433/244830>

RIGHT:

The full-text file will be made open to the public on 1 June 2020 in accordance with publisher's 'Terms and Conditions for Self-Archiving'.; This is not the published version. Please cite only the published version.; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。



Hypertension

Manuscript Submission and Peer Review System

Disclaimer: The manuscript and its contents are confidential,
intended for journal review purposes only, and not to be further
disclosed.

URL: <http://hype-submit.aha-journals.org>

Title: Staging Cardiac Damage in Patients with Hypertension

Manuscript number: HYPE201913797R2

Author(s): Takao Kato, Kyoto University, Graduate School of Medicine

Yuta Seko, Kyoto University, Graduate School of Medicine

Masayuki Shiba, Kyoto University, Graduate School of Medicine

Yusuke Morita, Tazuke Kofukai Foundation, Medical Research

Institute, Kitano Hospital

Yuhei Yamaji, Tazuke Kofukai Foundation, Medical Research Institute,

Kitano Hospital

Yoshisumi Haruna, Tazuke Kofukai Foundation, Medical Research

Institute, Kitano Hospital

Eisaku Nakane, Kitano Hospital, The Tazuke Kofukai Medical Research

Institute



Tetsuya Haruna, Kitano Hospital, The Tazuke Kofukai Medical Research Institute

Moriaki Inoko, Kitano Hospital

For Hypertension Peer Review. Do not distribute.
Destroy after use.

1 **Staging Cardiac Damage in Patients with Hypertension**

2 **Running title: Staging Cardiac Damage**

3 **Authors:** Yuta Seko¹; Takao Kato¹; Masayuki Shiba¹; Yusuke Morita²; Yuhei Yamaji²;

4 Yoshizumi Haruna²; Eisaku Nakane²; Tetsuya Haruna²; Moriaki Inoko²

5

6 **Affiliations:** ¹Department of Cardiovascular Medicine, Kyoto University Graduate School of

7 Medicine, Kyoto, Japan ²Cardiovascular Center, The Tazuke Kofukai Medical Research

8 Institute, Kitano Hospital, Osaka, Japan

9

10 **Corresponding author:** Takao Kato, MD

11 Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54

12 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan

13 Phone: +81-75-751-3190; Fax: +81-75-751-3203; E-mail: tkato75@kuhp.kyoto-u.ac.jp

14

15

16

17

18

19

Abstract

Ventricular and extraventricular response to pressure overload may be a common process in aortic stenosis and hypertension. We aimed to evaluate the association of a newly defined staging classification characterizing the extent of cardiac damage, originally developed for aortic stenosis, with long-term outcomes in patients with hypertension. We retrospectively analyzed 1639 patients with hypertension who had undergone both scheduled transthoracic echocardiography and electrocardiography in 2013 in a Japanese hospital, after excluding severe and moderate aortic stenosis, aortic regurgitation, mitral stenosis, previous myocardial infarction, or cardiomyopathy. We classified patients according to the presence or absence of cardiac damage as detected on echocardiography as follows: stage 0, no cardiac damage (n = 858; 52.3%); stage 1, left ventricular damage (n = 358; 21.8%); stage 2, left atrial or mitral valve damage (n = 360; 22.0%); or stage 3-4, pulmonary vasculature, tricuspid valve, or right ventricular damage (n = 63; 3.8%). The primary outcome was a composite of all-cause death and major adverse cardiac events. Cumulative 3-year incidence of the primary outcome was 15.5% in stage 0, 20.7% in stage 1, 31.8% in stage 2, and 60.6% in stage 3. After adjusting for confounders, the stage was incrementally associated with higher risk of the primary outcome (per 1-stage increase: HR, 1.46 [95% CI, 1.31-1.61]; $P < .001$). The staging classification characterizing the extent of cardiac damage, originally developed for aortic stenosis, was associated with long-term outcomes in patients with hypertension in a stepwise manner.

1 **Keywords:** staging; hypertension; clinical; retrospective, risk

2

3

4

5

For Hypertension Peer Review. Do not distribute.
Destroy after use.

1 Introduction

2 Hypertension is a major public health issue related to both cardiovascular and kidney
3 disease [1-3] and remains a serious problem associated with considerable morbidity and
4 mortality. Hypertension can cause structural and functional damage of the heart, involving
5 ventricular and atrial myocardium as well as epicardial and intramural coronary arteries [1,
6 4-7]. Previous studies reported definition and classification of "hypertensive heart disease"
7 based on the main changes to the heart induced by chronic blood pressure elevation: left
8 ventricular hypertrophy, atrial fibrillation, and combined ischemic heart disease [8-13].
9 However, no established staging definition is available and clinically meaningful
10 classification of hypertensive cardiac damage is currently unknown. Thus, there is urgent
11 need to develop individual risk stratification and subsequent treatment strategy for the given
12 patient with hypertension.

13 Recently, a new staging classification which characterizes the extent of cardiac
14 damage associated with aortic stenosis has important prognostic implications for clinical
15 outcomes from the view point of pressure overload due to stenotic valve [14-15]. This new
16 multiparametric staging system characterizes the extent of anatomical and functional cardiac
17 damage in patients with aortic stenosis. Ventricular and extraventricular response to pressure
18 overload may be common process in aortic stenosis and hypertension. Considering that aortic
19 stenosis and hypertension are characterized by the pressure overload and its response [16-19],

we hypothesized that this new staging classification for aortic stenosis may also be applicable to hypertension.

In the present study, we categorized the different types of cardiac damage (left ventricular dysfunction vs left atrial enlargement and mitral regurgitation vs pulmonary hypertension and right ventricular damage) in patients with hypertension using the staging classification for aortic stenosis used in previous studies [14, 15]. We also assessed the impact of these stages on long-term clinical outcomes in a Japanese hospital-based patients with hypertension.

Methods

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Study population

We retrospectively analyzed 4444 patients who had undergone simultaneous scheduled transthoracic echocardiography and electrocardiography at Kitano Hospital in 2013 [20-23] ordered at the physician's discretion. A flowchart of the study population is shown in Figure 1. We excluded patients with severe or moderate aortic stenosis (n=133), aortic regurgitation (n=133), mitral stenosis (n=9), previous myocardial infarction (n=420),

1 cardiomyopathy (n=271), or severe form of congenital heart disease or pericardial disease
2 (n=0) due to the effects of these conditions on cardiac dimensions. We also excluded patients
3 with incomplete or unavailable baseline echocardiogram study for review to allow for
4 adequate staging classification.

5 The study population comprised 1639 patients, who were categorized into 4 groups
6 depending on the presence or absence of hypertensive cardiac damage or dysfunction
7 detected on transthoracic echocardiography as follows: stage 0, no cardiac damage; stage 1,
8 left ventricular damage defined as presence of left ventricular hypertrophy (left ventricular
9 mass index $> 95 \text{ g/m}^2$ for women or $> 115 \text{ g/m}^2$ for men) [24], severe left ventricular
10 diastolic dysfunction ($E/e' > 14$), or left ventricular systolic dysfunction (left ventricular
11 ejection fraction $< 50\%$) [24]; stage 2, left atrium or mitral valve damage or dysfunction
12 defined as presence of enlarged left atrium ($> 34 \text{ mL/m}^2$), atrial fibrillation (from the
13 electrocardiogram database, we extracted data on cardiac rhythm and recorded them as they
14 were documented), or moderate or severe mitral regurgitation; or stage 3-4, pulmonary artery
15 vasculature or tricuspid valve damage or dysfunction defined as presence of systolic
16 pulmonary hypertension (systolic pulmonary arterial pressure $> 60 \text{ mmHg}$) or moderate or
17 severe tricuspid regurgitation. We did not have data on right ventricular function, although
18 patients with right ventricular dysfunction showed the features of stage 3; therefore, patients
19 with right ventricular dysfunction were included in stage 3-4. Patients were classified in a

given stage (worst stage) if at least 1 of the criteria was met within that stage [14, 15]. These criteria were adopted based on their broad acceptance, as markers of abnormal cardiac function, their simplicity of examination and used previous studies in patients with aortic stenosis [14]. In addition, we also analyzed the data using the modified staging classification in which stage 1 was defined as left ventricular hypertrophy and left ventricular ejection fraction <60% instead of <50% (Table S1) [25].

The research protocol was approved by the Institutional Review Board of Kitano Hospital (approval number: P16-02-005). Informed consent was waived due to the retrospective design of the study. We disclosed the details of the present study to the public as an opt-out method and the notice clearly informed patients of their right to refuse enrollment. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in a priori approval by the institution's Human Research Committee. Patients' records and information were anonymized and de-identified before analysis.

Data collection

Using the transthoracic echocardiography database, we extracted data regarding wall thickness, left ventricular diastolic dimensions, left ventricular systolic dimensions, left atrial dimension, left atrial volume index, left ventricular ejection fraction, and body mass index. From the electrocardiogram database, we extracted data on cardiac rhythm and recorded them as they were documented; therefore, we could not determine whether atrial fibrillation was

1 paroxysmal or persistent. Based on the transthoracic echocardiography data along with the
2 catheter suite's database, we identified patients who had previous myocardial infarction or
3 structural heart disease. Left ventricular mass index and relative wall thickness were
4 calculated using the formula recommended by the American Society of Echocardiography
5 [24]. Pulmonary systolic pressure was calculated as follows: right ventricular systolic
6 pressure was determined from the tricuspid regurgitation jet velocity using the simplified
7 Bernulli equation, and combining this value with an estimate of the right atrial pressure by
8 the diameter and collapsibility of the inferior vena cava that was added to the calculated
9 gradient to yield pulmonary systolic pressure [26, 27]. Tricuspid regurgitation was evaluated
10 in the apical four-chamber view, the parasternal short-axis view at the level of the aortic valve,
11 and the right ventricular inflow view. The e' was measured on the apical 4-chamber view,
12 while the E/e' ratio was calculated at the interventricular septum. Data from 2-dimensional
13 transthoracic echocardiography were analyzed at baseline. Left ventricular ejection fraction
14 was measured using the Teichholz method or modified Simpson rule. All transthoracic
15 echocardiography measurements were determined using the average of at least 3 cardiac
16 cycles. We also extracted patient information from their electronic medical records at our
17 institution, including age, sex, and type of disease (i.e., ischemic heart disease, *International*
18 *Statistical Classification of Diseases and Related Health Problems*, Tenth Edition [ICD-10]
19 codes I20, I21, I22, I23, I24, and I25; hypertension, ICD-10 codes I10, I11, I12, I13, I14, and

1 I15; dyslipidemia, ICD-10 code E78; diabetes mellitus, ICD-10 codes E10, E11, E12, E13,
2 and E14; and chronic kidney disease, ICD-10 code N18) [20-23]. Follow-up data from serial
3 clinic visits during June 2017 were also collected retrospectively from electronic medical
4 records [20-23].

5 **Outcome measures**

6 The primary outcome was a composite of all-cause death and major adverse cardiac events
7 defined as acute heart failure, acute myocardial infarction, unstable angina pectoris, cerebral
8 infarction, cerebral hemorrhage, and emerging aorta and peripheral vascular disease,
9 including treatment for aortic aneurysm, all of which required unplanned hospitalization.
10 Secondary outcomes were all-cause death and major adverse cardiac events, separately.

11 **Statistical analyses**

12 Categorical variables are presented as number and percentage and were compared
13 using the chi-square or Fisher exact test. Trends across the 3 groups were assessed using the
14 Cochran-Armitage trend test. Continuous variables are expressed as mean and standard
15 deviation (SD) or median and interquartile range (IQR); based on their distribution,
16 continuous variables were compared using 1-way analysis of variance or the Kruskal-Wallis
17 test.

18 We compared 3-year clinical outcomes according to stage of cardiac damage.
19 Cumulative incidence of clinical events was estimated using the Kaplan-Meier method and

intergroup differences were assessed using the log-rank test. Multivariable Cox proportional hazards models were used to estimate risk of the primary and secondary outcomes according to stage or in other clinically relevant risk-adjusted variables (age >80 years, male, diabetes mellitus, dyslipidemia, ischemic heart disease, and chronic kidney disease). Results were expressed as the hazard ratio (HR) and 95% confidence interval (CI). We selected the clinically relevant risk-adjusted variables (Table 1) for use in the main analysis. Next, we used a multivariable logistic regression model including stage as a continuous variable. Finally, we compared the net re-classification improvement level and integrated discrimination improvement degree among the original staging classification and the modified one regarding the improvement of prognosis prediction accuracy.

All statistical analyses were performed by physicians (Y.S., Y.M. and T.K.) using JMP version 14 (SAS Institute Inc, Chicago, IL, USA), R 3.4.1 (R Foundation for Statistical Computing, Austria), and the R package of survIDINRI (version 1.1.1). All reported P values were 2-tailed and those < .05 were considered statistically significant.

1 Results

2 Baseline clinical and echocardiographic characteristics

3 Of 1639 patients with hypertension, 858 (52.3%) were classified in stage 0, 358
4 (21.8%) in stage 1, 360 (22.0%) in stage 2, and 63 (3.8%) in stage 3-4 (Figure 1). Baseline
5 characteristics of the study population are presented in Table 1. There were significant
6 differences in age, sex, history of atrial fibrillation, diabetes, ischemic heart disease, chronic
7 kidney disease, and echocardiographic parameters among the groups (Table 1).

9 Clinical outcomes

10 Median follow-up duration after the index echocardiography was 1280 days (IQR,
11 755-1498 days), with a follow-up rate of 88.3%, 82.0%, and 75.0% at 1, 2, and 3 years,
12 respectively. Cumulative 3-year incidence of the primary and secondary outcomes increased
13 with each stage of cardiac damage (Figure 2A-C). After adjusting for confounders, excess
14 risk of the primary outcome in stage 2 (HR, 2.01 [95% CI, 1.57-2.57]; $P < .001$) and stage
15 3-4 (HR, 3.28 [95% CI, 2.20-4.75]; $P < .001$) relative to stage 0 remained significant (Table
16 2). Excess risk of all-cause death in stage 3-4 relative to stage 0 also remained significant
17 (HR, 3.33 [95% CI, 2.08-5.17]; $P < .001$). Excess risk of major adverse cardiac events in
18 stage 2 (HR, 3.10 [95% CI, 2.25-4.29]; $P < .001$) and stage 3-4 (HR, 4.68 [95% CI,
19 2.81-7.54]; $P < .001$) relative to stage 0 also remained significant (Table 2). Excess risk of the

primary outcome in other clinically relevant risk-adjusted variables are presented in Table S2.

When stage of cardiac damage was entered as a continuous variable in the multivariable model, the stage was incrementally associated with higher risk of the primary outcome (per 1-stage increase: HR, 1.46 [95% CI, 1.31-1.61]; $P < .001$) (Figure 2A), all-cause death (per 1-stage increase: HR, 1.31 [95% CI, 1.14-1.50]; $P < .001$) (Figure 2B), and major adverse cardiac events (per 1-stage increase: HR, 1.74 [95% CI, 1.52-1.99]; $P < .001$) (Figure 2C).

Subgroup analysis

We performed post hoc subgroup analysis stratified by the following factors: age > 70 years, sex, and comorbid disease (diabetes, dyslipidemia, ischemic heart disease, and chronic kidney disease) (Table 3). There were no interactions between presence or absence of age > 70 years, sex, diabetes, ischemic heart disease, or chronic kidney disease and stage for risk of the primary outcome. However, there was a significant interaction between presence of dyslipidemia, mild aortic stenosis and stage for incremental risk of the primary outcome.

Additional analysis using modified criteria

When we used the modified staging classification in which stage 1 was defined as left ventricular hypertrophy and left ventricular ejection fraction $<60\%$ instead of $<50\%$

1 (Table S1), the results were fully consistent with the main analysis (Figure S1A-C and Tables
2 S3 and S4). According to integrated discrimination improvement and net reclassification
3 improvement analysis (Table S5), the improvement of prognosis prediction accuracy did not
4 differ significantly between the modified staging and original one.

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

Discussion

The main finding of this study was that the new staging classification based on the extent of cardiac damage, originally proposed for aortic stenosis, was associated with long-term clinical outcomes in patients with hypertension.

Hypertension causes structural and functional cardiac changes, such as left ventricular and left atrial dilation as well as systolic and diastolic dysfunction [4-7].

Hypertensive cardiac damage encompasses a broad spectrum, including asymptomatic left ventricular hypertrophy and clinical heart failure. Several reports have discussed classification of hypertensive cardiac damage [8-13]. For example, in patients with hypertension, high left atrial volume index or high left ventricular mass index is associated with adverse cardiovascular risk profile and is a predictor of cardiovascular events [28-33]. However, a stepwise classification according to the extent of cardiac damage had not been proposed. To the best of our knowledge, this is the first report using a large clinical database to show an incremental association between extent of cardiac damage and long-term outcomes in patients with hypertension.

Both aortic stenosis and hypertension are associated with pressure overload [16-20].

With aortic stenosis progression, pressure overload leads to compensatory left ventricular hypertrophy, diastolic dysfunction, increased left atrial size, development of mitral regurgitation, and finally, development of pulmonary hypertension and right ventricular dysfunction [34, 35]. Previous studies have reported successful staging classification of aortic

1 stenosis according to the extent of cardiac damage not only in patients who underwent aortic
2 valve replacement but in symptomatic and asymptomatic patients [14, 15, 25, 36]. However,
3 as mentioned in these studies [14, 15, 25, 36], the stage classification of cardiac damage is
4 not limited to aortic stenosis. In the present study, this severity classification showed an
5 incremental association with adverse events in patients with hypertension who underwent
6 scheduled transthoracic echocardiography. Staging classification of cardiac damage,
7 originally proposed for aortic stenosis, fit well in patients with hypertension. Subgroup
8 analysis implied that the association of severity classification with clinical outcomes was
9 observed regardless of the presence or absence of comorbid disease. In the presence of
10 dyslipidemia, the association was directionally and strongly observed. This may be attributed
11 that hyperlipidemia may be linked to the atherosclerotic burden that led to the cardiovascular
12 events [37, 38]. The staging classification was associated with long-term outcomes in
13 hypertensive patients without mild aortic stenosis. However, there was an interaction between
14 presence of mild aortic stenosis and stage for incremental risk of the primary outcome in our
15 study. First, the small number of patients with mild aortic stenosis may hamper the association
16 between staging and outcomes in the present study. Second, mild aortic stenosis after
17 excluding patients with severe or moderate aortic stenosis may not match the staging, because
18 aortic stenosis is progressive [39]. Further research is needed in patients who had both
19 hypertension and aortic stenosis to draw solid conclusions. Although hypertension and aortic

stenosis may share some pathophysiologic mechanisms, we need to clarify the distinction of timeframe of natural course between aortic stenosis and hypertension. Aortic stenosis is progressive disease with limited ways to delay progression [14, 16] while hypertension can be treated and controlled with optimal therapy. Although we did not have the data on treatment of hypertension such as drug class or on the duration of hypertension, optimal management may have the impact of the subsequent staging classification and outcomes.

There is a considerable risk in patients with hypertension in our study; thus, there is a need to enhance risk stratification in this subset. Staging classification may reflect the adaptation and maladaptation to overload ranging from left ventricular hypertrophy stage, which may be asymptomatic phase but predispose to acute heart failure due to afterload mismatch, to pulmonary congestion due to left heart failure, which may be symptomatic. In the present study, the population analyzed was hospital-based patients with hypertension and who had undergone scheduled transthoracic echocardiography and electrocardiogram. Thus, caution must be exercised when extrapolating the present study results to general population. However, our study may indicate the importance of assessing left ventricular hypertrophy, left atrial size, diastolic function, and systolic function, all of which are measured in the context of routine clinical practice in out-patient clinic. For a given patient with hypertension, we might assess the risk stratification of patients with hypertension, along with the treatment of hypertension and intervention to life style.

This study had several limitations. First, electrocardiogram and transthoracic echocardiography were ordered at the discretion of the treating physician, with no standardized indications. Second, patient data were extracted from electronic medical records; thus, we did not have data regarding treatment of hypertension and duration of hypertension. Third, data on right ventricular function were lacking. Tricuspid annulus systolic velocity and/or tricuspid annular plane systolic excursion were not obtained. Fourth, as this was a single-center study performed in Japan, possible selection bias could not be excluded despite the large sample size. Further research is warranted to apply this result in non-Japanese patients. Fifth, although the echocardiographic parameters were usually obtained in the context of routine examination, measurement errors and variability might exist. Since the definition of each stage is a multiparameter approach, the staging did not rely on a single parameter.

Perspectives

This is the first report using a large clinical database to show an incremental association between extent of cardiac damage and long-term outcomes in patients with hypertension. Both hypertension and aortic stenosis are very common disorders in today's society. This study contributes the novel finding that a stage classification on cardiac damage originally proposed for aortic stenosis can also be applied to patients with hypertension. The

1 clinical implication of the present study is that assessment of staging cardiac damage based
2 on pressure overload is important for risk stratification in patients with hypertension as well
3 as for treatment of hypertension.

4

5 **Author contribution**

6 Y. S. and T. K.: conceived the design, and wrote manuscript. Y.S, Y.M., and T.K.: performed
7 statistical analysis, M. S., Y.M., Y. Y., Y. H., E. N., T. H. and M.I.: collected the data and
8 made critical revision.

9

10 **Source of Funding:** None

11

12 **Declarations of interest:** None

13

14

15

1 **References**

- 2 [1] Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. *Am J Cardiol*
3 2000;85:251-255.
- 4 [2] Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B,
5 Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A,
6 Heritier S, Li N, Perkovic V, Woodward M, MacMahon S. Blood Pressure Lowering
7 Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure
8 on major cardiovascular events in older and younger adults: meta-analysis of randomised
9 trials. *BMJ* 2008;336:1121-1123.
- 10 [3] Mensah GA, Croft JB, Giles WH. The heart, kidney, and brain as target organs in
11 hypertension. *Cardiol Clin* 2002;20:225-247.
- 12 [4] Drazner MH. The progression of hypertensive heart disease. *Circulation*.
13 2011;123(3):327-334.
- 14 [5] De Simone G, Kitzman DW, Chinali M, Oberman A, Hopkins PN, Rao DC, Arnett DK,
15 Devereux RB. Left ventricular concentric geometry is associated with impaired relaxation
16 in hypertension: the HyperGEN study. *Eur Heart J* 2005;26:1039-1045.
- 17 [6] Kostis JB. From hypertension to heart failure: update on the management of systolic and
18 diastolic dysfunction. *Am J Hypertens* 2003;16(Suppl 2):18S-22S.
- 19 [7] Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, Carluccio E,

- 1 Sardone MG, Porcellati C. Atrial fibrillation in hypertension: predictors and outcome.
- 2 Hypertension 2003;41:218-223.
- 3 [8] González-Maqueda I, Alegría Ezquerro E, González Juanatey JR. Hypertensive heart
- 4 disease: a new clinical classification (VIA) An article from the E-Journal of the ESC
- 5 Council for Cardiology Practice. E-Journal of Cardiology Practice 2009; 7: N° 20
- 6 [9] Frohlich ED. Evaluation and management of the patients with essential hypertension. In:
- 7 Parmley WW, Chatterjee K, eds. Cardiology. Philadelphia: Lippincott, 1989;23:1-15.
- 8 [10] Subcommittee of WHO/ISH Mild Hypertension Liaison Committee. Summary of 1993
- 9 World Health Organisation-International Society of Hypertension: Guidelines for the
- 10 management of mild hypertension. Br Med J 1993;307:1541-1546.
- 11 [11] Savage DD, Garrison RJ, Kannel WB, Levy D, Anderson SJ, Stokes J, Feinleib M,
- 12 Castelli WP. The spectrum of left ventricular hypertrophy in a general population sample:
- 13 the Framingham study. Circulation 1987;75(Suppl 1):26-33.
- 14 [12] Ganau A, Devereux RB, Roman MJ, De Simone G, Pickering TG, Saba PS, Vargiu P,
- 15 Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and geometric
- 16 remodeling in essential hypertension. J Am Coll Cardiol 1992;19:1550-1558.
- 17 [13] Iriarte MM, Murga N, Sagastagoitia JD, Morillas M, Boveda J, Molinero E, et al.
- 18 Classification of hypertensive cardiomyopathy. Eur Heart J 1993;14(Suppl J):95-101.
- 19 [14] Genereux P, Pibarot P, Redfors B, Mack MJ, Makkar RR, Jaber WA, Svensson LG,

- 1 Kapadia S, Tuzcu EM, Thourani VH, Babaliaros V, Herrmann HC, Szeto WY, Cohen DJ,
- 2 Lindman BR, McAndrew T, Alu MC, Douglas PS, Hahn RT, Kodali SK, Smith CR,
- 3 Miller DC, Webb JG, Leon MB. Staging classification of aortic stenosis based on the
- 4 extent of cardiac damage. *Eur Heart J.* 2017;38(45):3351-3358.
- 5 [15] Fukui M, Gupta A, Abdelkarim I, Sharbaugh MS, Althouse AD, Elzomor H , Mulukutla
- 6 S, Lee JS, Schindler JT, Gleason TG, Cavalcante JL. Association of Structural and
- 7 Functional Cardiac Changes With Transcatheter Aortic Valve Replacement Outcomes in
- 8 Patients With Aortic Stenosis. *JAMA Cardiol.* 2019. (3)
- 9 [16] Genereux P, Stone GW, O'Gara PT, Marquis-Gravel G, Redfors B, Giustino G, Pibarot P,
- 10 Bax JJ, Bonow RO, Leon MB. Natural History, Diagnostic Approaches, and Therapeutic
- 11 Strategies for Patients With Asymptomatic Severe Aortic Stenosis. *J Am Coll Cardiol.*
- 12 2016;67(19):2263-2288.
- 13 [17] Turina J, Hess O, Sepulcri F, Krayenbuehl HP. Spontaneous course of aortic valve
- 14 disease. *Eur Heart J.* 1987 May;8(5):471-483.
- 15 [18] Faggiano P, Ghizzoni G, Sorgato A, Sabatini T, Simoncelli U, Gardini A, Rusconi C.
- 16 Rate of progression of valvular aortic stenosis in adults. *Am J Cardiol.* 1992 Jul
- 17 15;70(2):229-233.
- 18 [19] Barbieri A, Bartolacelli Y, Bursi F, Manicardi M, Boriani G. Remodeling classification
- 19 system considering left ventricular volume in patients with aortic valve stenosis:

- 1 Association with adverse cardiovascular outcomes. Echocardiography (Mount Kisco,
- 2 NY). 2019;36(4):639-650.
- 3 [20] Seko Y, Kato T, Haruna T, Izumi T, Miyamoto S, Nakane E, Inoko M. Association
- 4 between atrial fibrillation, atrial enlargement, and left ventricular geometric remodeling.
- 5 Scientific Reports. 2018;8(1):6366.
- 6 [21] Seko Y, Kato T, Morita Y, Yamaji Y, Haruna Y, Izumi T, Miyamoto S, Nakane E, Hayashi
- 7 H, Haruna T, Inoko M. Impact of left ventricular concentricity on long-term mortality in a
- 8 hospital-based population in Japan. PLoS One. 2018;13(8):e0203227.
- 9 [22] Seko Y, Kato T, Morita Y, Yamaji Y, Haruna Y, Izumi T, Miyamoto S, Nakane E, Hayashi
- 10 H, Haruna T, Inoko M. Age- and Body Size-Adjusted Left Ventricular End-Diastolic
- 11 Dimension in a Japanese Hospital-Based Population. Circ J. 2019;83(3):604-613.
- 12 [23] Seko Y, Kato T, Morita Y, Yamaji Y, Haruna Y, Nakane E, Haruna T, Inoko M.
- 13 Association with left atrial volume index and long-term prognosis in patients without
- 14 systolic dysfunction nor atrial fibrillation: an observational study. Heart Vessels. 2019 doi:
- 15 10.1007
- 16 [24] Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA,
- 17 Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel
- 18 ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber
- 19 quantification by echocardiography in adults: an update from the American Society of

- 1 Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc
- 2 Echocardiogr. 2015;28:1-39 e14.
- 3 [25] Tastet L, Tribouilloy C, Marechaux S, Vollema EM, Delgado V, Salaun E, Shen M,
- 4 Capoulade R, Clavel MA, Arsenault M, Bédard É, Bernier M, Beaudoin J, Narula J,
- 5 Lancellotti P, Bax JJ, Gèneux P, Pibarot P. Staging Cardiac Damage in Patients With
- 6 Asymptomatic Aortic Valve Stenosis. J Am Coll Cardiol. 2019;74(4):550-563.
- 7 [26] Lai WW, Gauvreau K, Rivera ES, Saleeb S, Powell AJ, Geva T. Accuracy of
- 8 noninvasively determined pulmonary artery systolic pressure. Am J Cardiol.
- 9 2010;105(8):1192-7.
- 10 [27] Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K,
- 11 Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of
- 12 the right heart in adults: a report from the American Society of Echocardiography
- 13 endorsed by the European Association of Echocardiography, a registered branch of the
- 14 European Society of Cardiology, and the Canadian Society of Echocardiography. J Am
- 15 Soc Echocardiogr. 2010;23(7):685-713; quiz 86-8.
- 16 [28] Mancusi C, Canciello G, Izzo R, Damiano S, Grimaldi MG, de Luca N, de Simone G,
- 17 Trimarco B, Losi MA. Left atrial dilatation: A target organ damage in young to
- 18 middle-age hypertensive patients. The Campania Salute Network. Int J Cardiol.
- 19 2018;265:229-233.

- 1 [29] Kanar B, Ozben B, Kanar HS, Arsan A, Tigen K. Left atrial volume changes are an early
- 2 marker of end-organ damage in essential hypertension: A multidisciplinary approach to an
- 3 old problem. *Echocardiography* (Mount Kisco, NY). 2017;34(12):1895-1902.
- 4 [30] Piotrowski G, Banach M, Gerdts E, Mikhailidis DP, Hannam S, Gawor R, Stasiak A,
- 5 Rysz J, Gawor Z. Left atrial size in hypertension and stroke. *Journal of hypertension*.
- 6 2011;29(10):1988-1993.
- 7 [31] Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular
- 8 mass and geometry to morbidity and mortality in uncomplicated essential hypertension.
- 9 *Ann Intern Med* 1991; 114:345–352.
- 10 [32] Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, Solinas P,
- 11 Gorini M, Maggioni AP, MAVI (MASSA Ventricolare sinistra nell'Ipertensione) Study
- 12 Group. Left ventricular mass and cardiovascular morbidity in essential hypertension: the
- 13 MAVI study. *J Am Coll Cardiol* 2001; 38:1829–1835.
- 14 [33] Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous
- 15 relation between left ventricular mass and cardiovascular risk in essential hypertension.
- 16 *Hypertension* 2000; 35:580-586.
- 17 [34] Dahl JS, Barros-Gomes S, Videbæk L, Poulsen MK, Issa IF, Carter-Storch R,
- 18 Christensen NL, Kumme A, Pellikka PA, Møller JE. Early diastolic strain rate in relation
- 19 to systolic and diastolic function and prognosis in aortic stenosis. *JACC Cardiovasc*

- 1 Imaging. 2016;9(5):519-528.
- 2 [35] Dahl JS, Videbæk L, Poulsen MK, Pellikka PA, Veien K, Andersen LI, Haghfelt T,
- 3 Møller JE. Noninvasive assessment of filling pressure and left atrial pressure overload in
- 4 severe aortic valve stenosis: relation to ventricular remodeling and clinical outcome after
- 5 aortic valve replacement. J Thorac Cardiovasc Surg. 2011;142(3):e77-e83.
- 6 [36] Vollema EM, Amanullah MR, Ng ACT, van der Bijl P, Prevedello F, Sin YK, Prihadi EA,
- 7 Marsan NA, Ding ZP, G  n  reux P, Pibarot P, Leon MB, Narula J, Ewe SH, Delgado V,
- 8 Bax JJ. Staging Cardiac Damage in Patients With Symptomatic Aortic Valve Stenosis. J
- 9 Am Coll Cardiol. 2019;74(4):538-549.
- 10 [37] Schuurman AS, Vroegindewey MM, Kardys I, Oemrawsingh RM, Garcia-Garcia HM,
- 11 van Geuns RJ, Regar E, Van Mieghem NM, Ligthart J, Serruys PW, Boersma E,
- 12 Akkerhuis KM. Prognostic Value of Intravascular Ultrasound in Patients With Coronary
- 13 Artery Disease. J Am Coll Cardiol. 2018 Oct 23;72(17):2003-2011.
- 14 [38] Nezu T, Hosomi N, Aoki S, Matsumoto M. Carotid Intima-Media Thickness for
- 15 Atherosclerosis. J Atheroscler Thromb. 2016;23(1):18-31.
- 16 [39] Taniguchi T, Morimoto T, Shiomi H, Ando K, Kanamori N, Murata K, et al. Initial
- 17 Surgical Versus Conservative Strategies in Patients With Asymptomatic Severe Aortic
- 18 Stenosis. J Am Coll Cardiol. 2015;66(25):2827-2838.
- 19

1 **Novelty and Significance:**

2 **1) What Is New?**

3 This is the first report using a large clinical database to show an incremental association
4 between extent of cardiac damage and long-term outcomes in patients with hypertension.

5 **2) What Is Relevant?**

6 This study has the novel finding that a stage classification on cardiac damage originally
7 proposed for aortic stenosis can also be applied to patients with hypertension.

8 **Summary**

9 The clinical implication of the present study is that assessment of staging cardiac damage
10 based on pressure overload is important for risk stratification in patients with hypertension as
11 well as for treatment of hypertension.

12

13

14

15

16

17

18

19

1 **Figure Legends**

2 **Fig 1. Flowchart of the study population**

3 AR, aortic regurgitation; AS, aortic stenosis; E, transmitral early filling velocity; e', early
4 diastolic mitral annular velocity; ECG, electrocardiography; LAVI, left atrial volume index;
5 LV, left ventricle; LVMI, left ventricular mass index; LVEF, left ventricular ejection fraction;
6 MR, mitral regurgitation; MS, mitral stenosis; OMI, old myocardial infarction; RV; right
7 ventricle; TTE, transthoracic echocardiography.

8 **Fig 2. Cumulative incidence of the primary outcome (a composite of all-cause death and** 9 **MACE) and secondary outcomes (all-cause death or MACE)**

10 (A)Composite of all-cause death and MACE. (B) All-cause death. (C) MACE. MACE was
11 defined as acute heart failure, acute myocardial infarction, unstable angina pectoris, cerebral
12 infarction, cerebral hemorrhage, aortic dissection, or treatment for aortic aneurysm. MACE,
13 major adverse cardiac events.

14

15